Eptifibatide Injection

Platelet aggregation is the core process of hemostasis and thrombus formation, which is divided into three consecutive stages: adhesion, activation, and aggregation, forming a complete signaling cascade reaction.
Initiation phase: Platelet adhesion

After adhesion, ADP, 5-hydroxytryptamine, and thromboxane A ₂ (TXA ₂) are locally released, and thrombin is activated to form various agonist signals. These agonists bind to corresponding receptors on the surface of platelets (P2Y ₁₂, TP, PAR-1, etc.), triggering intracellular Ca ² ⁺ release, cAMP decrease, PKC activation, initiating signal transduction from the inside out, causing conformational remodeling of GP IIb/IIIa receptors from low affinity to high affinity activated state. This stage is signal amplification, which is a prerequisite for platelet aggregation.

GP IIb/IIIa receptors (integrin α IIb β ∝) are the most abundant and functionally core receptors on the surface of platelets, determining their ability to aggregate.
molecular structure
A heterodimer with a molecular weight of approximately 240 kDa is formed by non covalent bonding between two subunits, α IIb (GP IIb) and β ∝ (GP IIIa).
Extracellular region: containing ligand binding domains (RGD/KGD recognition site, fibrinogen gamma chain binding site), Ca ² ⁺/Mn ² ⁺ binding region (regulating conformation).

Conformal state: at rest, it is a bent low affinity conformation; When activated, it is an extended high affinity conformation, with ligand affinity increased by 1000-10000 times.
Core ligand
Fibrinogen: the main ligand that binds to GP IIb/IIIa at both ends and mediates platelet cross-linking.
VWF: The main ligand under high shear forces (such as arteries and narrowed blood vessels), mediating firm platelet aggregation.
Other: Fibronectin, Hyaluronidase (minor role).

Traditional antiplatelet drugs (aspirin, P2Y12 inhibitors) only block a single upstream agonist pathway (such as aspirin blocking TXA ₂, clopidogrel blocking ADP), and cannot inhibit aggregation induced by other agonists, leading to treatment evasion.
The GP IIb/IIIa receptor is the only common terminal target, and blocking this pathway can comprehensively inhibit all agonist induced platelet aggregation, achieving complete antithrombotic effects.

The necessity of circular conformation
Linear peptides are easily degradable and conformally unstable, while circular structures resist protease hydrolysis and maintain precise spatial orientation of KGD, resulting in a 100 fold increase in receptor affinity.
The circular structure simulates the C-terminal circular binding domain of fibrinogen gamma chain, which binds to the receptor key and has strong specificity.
The core role of KGD motif
Natural fibrinogen contains two binding sites, RGD (Arg Gly Asp) and gamma chain KGD; The affinity of eptibatide KGD for activating GP IIb/IIIa is about 10 times higher than RGD, and the selectivity is stronger.

The precise simulation of GP IIb/IIIa binding epitopes of fibrinogen/vWF by eptibatide:
The spatial size, charge distribution, hydrophobic region, and natural ligand are highly homologous.
Compete with higher affinity to occupy the receptor ligand binding pocket, completely blocking fibrinogen/vWF binding without cross activation.
Non covalent binding with receptors (hydrogen bonding, electrostatic, hydrophobic interactions) lays the foundation for reversible blockade.